To further aid clinicians to choose the most optimal therapy for their PCa patients, a deeper understanding about the biological effects of PSMA-TAT, and more knowledge about the potential differences between e.g. lutetium-177-labeled and actinium-225-labeled PSMA-tracers, is indispensable. This evidence concerns the gene FOLH1 and posterior cortical atrophy.